Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2024 10:00 ET | Source: OncLive®

OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers announce recipients of the 2024 Luminary Awards in GI Cancers

CRANBURY, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and the Ruesch Center for the Cure of Gastrointestinal (GI) Cancers at...
October 11, 2023 10:55 ET | Source: OncLive®

OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2023 Luminary Awards in GI Cancers

CRANBURY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
January 25, 2023 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer

AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of...
November 09, 2022 09:00 ET | Source: OncLive®

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2022 Luminary Awards in Gastrointestinal Cancers

CRANBURY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- OncLive®, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
August 30, 2022 09:15 ET | Source: Verified Market Research

Gastrointestinal Stents Market size worth $ 579.4 Million, Globally, by 2030 at 4.80% CAGR: Verified Market Research®

Jersey City, New Jersey, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Gastrointestinal Stents Market” By Product (Biliary Stent, Duodenal Stent, Colonic...
January 17, 2019 08:00 ET | Source: Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium

Newark, NJ, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the study plan for a Phase 3...
October 16, 2018 12:05 ET | Source: PanTher Therapeutics

PanTher Therapeutics Announces Agreement with MD Anderson Cancer Center and Appointment of Senior Clinical Advisor

CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE NEWSWIRE) -- PanTher Therapeutics, the biotech company developing drug-delivery platforms for unresectable, locally advanced solid tumors, today announced an...
July 06, 2018 10:38 ET | Source: American Health Council

John Inadomi, MD is Honored by the American Health Council for “Best in Medicine”

NEW YORK, July 06, 2018 (GLOBE NEWSWIRE) -- The American Health Council is proud to honor John Inadomi, MD as “America’s Best Doctor” for his contributions to the gastrointestinal field. Currently a...